Dr. Edwards is a genetic epidemiologist with extensive experience in the design, collection, and statistical analyses of family data and case-control studies. Her primary work focuses on identifying quantitative phenotypes for complex diseases. Dr. Edwards is Director of the PANUC Data Management and Biostatistics Core. This Core will provide statistical and study design support through database development, statistical and methodological support, data analysis, and interpretation of results.
Dr. Leverenz is a neurologist and neuropathologist with extensive experience in clinical and neuropathologic research in neurodegenerative diseases, particularly those associated with Lewy-related pathology, including Parkinson’s disease. He is Co-Director of the Washington Parkinson’s Disease Registry (WPDR). Dr. Leverenz is the Core Leader of the PANUC’s Clinical Core at the University of Washington and the Seattle VA Medical Center. The primary goal of the Clinical Core will be to support PANUC through longitudinal characterization of PD subjects and the generation of biological samples needed for biomarker and genetic research projects. This study will improve our understanding of what causes PD-associated cognitive decline, with the long-term objective of developing better treatments for this disabling facet of PD.
Dr. Montine is a neuropathologist with research interests in the structural and molecular bases of cognitive impairment in Alzheimer’s and Parkinson’s diseases. The goal of his work is to define key pathogenic steps and thereby identify new potential therapeutic targets through a combination of epidemiology-related neuropathology, biomarkers for clinical trials, and experimental studies. Dr. Montine is the Program Director of PANUC and the Project Leader of Project 2, entitled “Selective and Restricted Denervation in Parkinson’s Disease with Cognitive Impairment.” This project will provide rationale for new evidence-based interventions for cognitive impairment in Parkinson’s disease beyond dopamine replacement strategies.
Dr. Palmiter has been studying the role of neurotransmitters in the development and function of the nervous system for over twenty years. Dr. Palmiter is the Project Leader of PANUC Project 1 entitled “Functional and Anatomical Analysis of Dopaminergic Projections That Mediate Cognition.” This project will endeavor to distinguish between the effects of loss of dopamine signaling and dopamine neuron degeneration on cognitive abilities.
Dr. Quinn is a neurologist who specializes in neurodegenerative diseases associated with dementia, including Alzheimer's disease and Parkinson's disease. He is engaged in translational research aimed at developing new therapies for neurodegenerative dementias, with research activity ranging from animal models of neurodegeneration to biomarker studies to clinical trials. Dr. Quinn is the Director of the PANUC Clinical Core at Oregon Health & Science University (OHSU) and the Portland VA Medical Center.
Dr. Zabetian is a neurologist who specializes in neurogenetics and Parkinson’s disease. He is the Director of the Parkinson’s Genetic Research Study (PaGeR) in Seattle and Co-Director of the Washington Parkinson’s Disease Registry (WPDR). Dr. Zabetian is Co-Director of the PANUC Genetics-Biomarker-Neuropathology Core and the Project Leader of PANUC Project 3, entitled “Genetic Risk Factors for Cognitive Impairment in Parkinson’s Disease.” This project will endeavor to increase our understanding of the genetic processes that underlie cognitive impairment in Parkinson’s disease in order to identify new therapeutic targets to help prevent and better treat this disabling facet of Parkinson’s disease.
Dr. Zhang is a neuropathologist whose research focuses on understanding the molecular mechanisms of Parkinson’s disease development and progression, including identifying unique biomarkers. Dr. Zhang is Director of the PANUC Genetics-Biomarkers-Neuropathology Core. Biomarkers validated in the Core will be important in aiding in the diagnosis of cognitive impairment in patients with Parkinson’s disease as well as monitoring progression and evaluating effectiveness of therapeutics. Dr. Zhang is also the Principal Investigator of a linked R01 that is focused on discovering biomarkers related to Parkinson’s disease diagnosis and progression, including development of cognitive impairment in Parkinson’s disease patients.